New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Pfizer Inc.

PFE

Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−9.68%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

27.68 0.11 +0.40%
Market cap
$158.2B
P/E
38.8×
Fwd P/E FY26e
18.7×
Dividend yield
6.24%
F-score
6/9
ROIC
6.19%
Net debt / EBITDA
2.5×
Payout ratio
2.5×

Pfizer Inc. 10-Q filed Nov 3, 2026

Fiscal Q3 2026 · Period ended Sep 27, 2026 · Filed · accepted 8:19 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 4, 2026: 14 added · 11 removed · 67 modified; 4 with only figures updated; 2 moved without change

  1. Modified · Restructuring Programs

    Manufacturing Optimization Program––In the third quarter of 2026, we announced the next phase of our multi-year program designed to reduce our cost of goods sold focused on network structure changes, product portfolio enhancements and additional operational efficiencies which is expected to deliver additional anticipated savings of approximately $1.5 billion through 2029, some of which is expected to begin being realized in 2027from 2027 through 2029. The one-time costs to achieve the savings associated with this phase of the program are expected to be approximately $4.0 billion, with approximately 60% ofrepresenting non-cash expenditures. The costs to achieve these savings are expected to be incurred through 2029.

91 more changes in this Item, word by word, in Powerpack.